{"id":"https://openalex.org/W2013681945","doi":"https://doi.org/10.1002/ddr.430300307","title":"Hypotensive responses to the putative adenosine A3 receptor agonist N6\u20102\u2010(4\u2010aminophenyl)\u2010ethyladenosine in the rat","display_name":"Hypotensive responses to the putative adenosine A3 receptor agonist N6\u20102\u2010(4\u2010aminophenyl)\u2010ethyladenosine in the rat","publication_year":1993,"publication_date":"1993-11-01","ids":{"openalex":"https://openalex.org/W2013681945","doi":"https://doi.org/10.1002/ddr.430300307","mag":"2013681945"},"language":"en","primary_location":{"id":"doi:10.1002/ddr.430300307","doi":"https://doi.org/10.1002/ddr.430300307","is_oa":false,"landing_page_url":"https://doi.org/10.1002/ddr.430300307","pdf_url":null,"source":{"id":"https://openalex.org/S26306840","display_name":"Drug Development Research","issn_l":"0272-4391","issn":["0272-4391","1098-2299"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug Development Research","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5111648867","display_name":"Alan M. Carruthers","orcid":"https://orcid.org/0009-0008-2701-672X","observed_orcids":["https://orcid.org/0009-0008-2701-672X"]},"institutions":[{"id":"https://openalex.org/I4388891806","display_name":"Sandoz Group AG (Switzerland)","ror":"https://ror.org/02rse7p59","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4388891806"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Alan M. Carruthers","raw_affiliation_strings":["Preclinical Research, Sandoz Pharma Ltd., Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Preclinical Research, Sandoz Pharma Ltd., Basel, Switzerland","institution_ids":["https://openalex.org/I4388891806"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5103521640","display_name":"John R. Fozard","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4388891806","display_name":"Sandoz Group AG (Switzerland)","ror":"https://ror.org/02rse7p59","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4388891806"]}],"countries":["CH"],"is_corresponding":true,"raw_author_name":"John R. Fozard","raw_affiliation_strings":["Preclinical Research, Sandoz Pharma Ltd., Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Preclinical Research, Sandoz Pharma Ltd., Basel, Switzerland","institution_ids":["https://openalex.org/I4388891806"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5103521640"],"corresponding_institution_ids":["https://openalex.org/I4388891806"],"apc_list":{"value":3980,"currency":"USD","value_usd":3980},"apc_paid":null,"fwci":0.8941,"has_fulltext":false,"cited_by_count":10,"citation_normalized_percentile":{"value":0.7195371,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"30","issue":"3","first_page":"147","last_page":"152"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11193","display_name":"Adenosine and Purinergic Signaling","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/1314","display_name":"Physiology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11193","display_name":"Adenosine and Purinergic Signaling","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/1314","display_name":"Physiology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11001","display_name":"Renin-Angiotensin System Studies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T14486","display_name":"Cardiovascular, Neuropeptides, and Oxidative Stress Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/a3-adenosine-receptor","display_name":"A3 adenosine receptor","score":0.9620000123977661},{"id":"https://openalex.org/keywords/apnea","display_name":"apnea","score":0.9430000185966492},{"id":"https://openalex.org/keywords/hypotension","display_name":"hypotension","score":0.828000009059906},{"id":"https://openalex.org/keywords/dpcpx","display_name":"DPCPX","score":0.7680000066757202},{"id":"https://openalex.org/keywords/adenosine-a1-receptor","display_name":"adenosine A1 receptor","score":0.753000020980835},{"id":"https://openalex.org/keywords/cyclopentyladenosine","display_name":"cyclopentyladenosine","score":0.8989999890327454},{"id":"https://openalex.org/keywords/bradycardia","display_name":"bradycardia","score":0.8730000257492065},{"id":"https://openalex.org/keywords/nitric-oxide","display_name":"nitric oxide","score":0.7350000143051147},{"id":"https://openalex.org/keywords/atp-sensitive-potassium-channels","display_name":"ATP-sensitive potassium channels","score":0.8130000233650208},{"id":"https://openalex.org/keywords/glibenclamide","display_name":"glibenclamide","score":0.9760000109672546},{"id":"https://openalex.org/keywords/angiotensin-ii","display_name":"angiotensin II","score":0.9179999828338623},{"id":"https://openalex.org/keywords/phenylephrine","display_name":"phenylephrine","score":0.8640000224113464},{"id":"https://openalex.org/keywords/clonidine","display_name":"clonidine","score":0.8500000238418579},{"id":"https://openalex.org/keywords/l-name","display_name":"L-NAME","score":0.777999997138977},{"id":"https://openalex.org/keywords/receptor-selectivity","display_name":"receptor selectivity","score":0.4339999854564667}],"concepts":[{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.7067969441413879},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.6746776700019836},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6627548933029175},{"id":"https://openalex.org/C2779768347","wikidata":"https://www.wikidata.org/wiki/Q420626","display_name":"Glibenclamide","level":3,"score":0.6358005404472351},{"id":"https://openalex.org/C2776991684","wikidata":"https://www.wikidata.org/wiki/Q190012","display_name":"Adenosine","level":2,"score":0.562007486820221},{"id":"https://openalex.org/C2777952589","wikidata":"https://www.wikidata.org/wiki/Q421910","display_name":"Phenylephrine","level":3,"score":0.5133606791496277},{"id":"https://openalex.org/C2779470414","wikidata":"https://www.wikidata.org/wiki/Q50980","display_name":"Xanthine","level":3,"score":0.5001096725463867},{"id":"https://openalex.org/C182683403","wikidata":"https://www.wikidata.org/wiki/Q14888579","display_name":"Adenosine A1 receptor","level":5,"score":0.4814107418060303},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.48041394352912903},{"id":"https://openalex.org/C2908929049","wikidata":"https://www.wikidata.org/wiki/Q65963433","display_name":"Angiotensin II","level":3,"score":0.4501887261867523},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3687022030353546},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.362640917301178},{"id":"https://openalex.org/C67907053","wikidata":"https://www.wikidata.org/wiki/Q356147","display_name":"Adenosine receptor","level":4,"score":0.35324910283088684},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.33420228958129883},{"id":"https://openalex.org/C84393581","wikidata":"https://www.wikidata.org/wiki/Q82642","display_name":"Blood pressure","level":2,"score":0.13368400931358337},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.12001976370811462},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.0},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1002/ddr.430300307","doi":"https://doi.org/10.1002/ddr.430300307","is_oa":false,"landing_page_url":"https://doi.org/10.1002/ddr.430300307","pdf_url":null,"source":{"id":"https://openalex.org/S26306840","display_name":"Drug Development Research","issn_l":"0272-4391","issn":["0272-4391","1098-2299"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug Development Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9074000120162964}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":8,"referenced_works":["https://openalex.org/W1535611266","https://openalex.org/W2022661890","https://openalex.org/W2037775910","https://openalex.org/W2039902122","https://openalex.org/W2046476854","https://openalex.org/W2055743341","https://openalex.org/W2084839593","https://openalex.org/W2320265671"],"related_works":["https://openalex.org/W2046476854","https://openalex.org/W2050751134","https://openalex.org/W2000675468","https://openalex.org/W2046244903","https://openalex.org/W2010310682","https://openalex.org/W2022661890","https://openalex.org/W2072161009","https://openalex.org/W2094685160","https://openalex.org/W2039902122","https://openalex.org/W4231477443"],"abstract_inverted_index":{"Abstract":[0],"The":[1,69,101],"hypotensive":[2,31,71,113,126,161],"response":[3,32,114,127,162],"to":[4,33,37,57,61,73,115,128,163],"the":[5,30,55,62,90,112,124,141,157],"putative":[6,158],"adenosine":[7],"A3":[8,159],"receptor":[9,65],"agonist,":[10,66],"N6\u20102\u2010(4\u2010aminophenyl)ethyladenosine":[11],"(APNEA),":[12],"has":[13],"been":[14],"further":[15],"investigated.":[16],"In":[17],"pithed":[18,79],"rats":[19],"with":[20,27,120],"blood":[21,82],"pressures":[22,83],"maintained":[23,85],"at":[24,42],"normal":[25],"values":[26],"angiotensin":[28,121],"II,":[29],"APNEA":[34,58,74,116,129],"was":[35],"resistant":[36],"blockade":[38],"by":[39,86],"1,3\u2010dipropyl\u20108\u2010cyclopentylxanthine":[40],"(DPCPX)":[41],"a":[43,136],"dose":[44],"of":[45,92,103,143,151],"0.5":[46],"mg":[47],"kg":[48],"(1.7":[49],"\u03bcmol":[50],"kg)":[51],"iv,":[52],"which":[53],"abolished":[54],"bradycardia":[56],"and":[59],"that":[60],"prototype":[63],"A1":[64],"N6\u2010cyclopentyladenosine":[67],"(CPA).":[68],"xanthine\u2010resistant":[70,125],"responses":[72],"were":[75,84],"broadly":[76],"similar":[77],"in":[78,117],"animals":[80,118],"whose":[81],"phenylephrine,":[87],"clonidine,":[88],"or":[89],"inhibitor":[91],"nitric":[93],"oxide":[94],"(NO)":[95],"synthase,":[96],"NG\u2010nitro\u2010L\u2010arginine":[97],"methyl":[98],"ester":[99],"(L\u2010NAME).":[100],"blocker":[102],"ATP\u2010dependent":[104],"potassium":[105],"(KATP)":[106],"channels,":[107],"glibenclamide,":[108],"did":[109],"not":[110,131],"affect":[111],"infused":[119],"II.":[122],"Thus,":[123],"is":[130],"an":[132],"effect":[133],"dependent":[134],"on":[135],"particular":[137],"agonist\u2010receptor":[138],"interaction.":[139],"Neither":[140],"release":[142],"NO,":[144],"newly":[145],"synthesized":[146],"from":[147],"L\u2010arginine,":[148],"nor":[149],"activation":[150],"glibenclamide\u2010sensitive":[152],"KATP":[153],"channels":[154],"can":[155],"explain":[156],"receptor\u2010mediated":[160],"APNEA.":[164],"\u00a9":[165],"1993":[166],"wiley\u2010Liss,":[167],"Inc.":[168]},"counts_by_year":[{"year":2016,"cited_by_count":1}],"updated_date":"2026-11-03T10:50:19.383937","created_date":"2016-06-24T00:00:00"}